Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

EDCTP approves € 80 M of funding to boost HIV/AIDS, TB and malaria research

04.06.2008
The European & Developing Countries Clinical Trials Partnership (EDCTP) has approved over € 80 million for research into prevention of HIV/AIDS, tuberculosis and malaria in Africa. This sum is the highest amount of EDCTP funding approved to date. The approval marks an increase of European investment in research into the three poverty-related diseases and is expected to significantly enhance cooperation between European and African researchers.

EDCTP is a partnership of 14 European Member States plus Norway, Switzerland and sub-Saharan countries. The Partnership aims to reduce the global burden of HIV/AIDS, TB and malaria by pooling resources for conducting clinical trials in sub-Saharan Africa. The current approval of funding consists of a contribution from the European Commission of € 40 M, to be matched by European Member States and third parties. The projects involve 12 European countries and 22 sub-Saharan African countries. Funding was approved in the following areas:

Tuberculosis Vaccines
Malaria Treatment
Malaria in Pregnancy
Malaria Vaccines
Ethics review capacity
WHO regulatory affairs
Networks of Excellence
Senior Fellowships
Additional funding in the areas of HIV treatment, vaccines and microbicides, TB treatment and Networks of Excellence is expected to be approved in the second half of 2008.

The projects on TB and malaria that will be funded combine clinical trials with capacity building and networking activities. By integrating these activities EDCTP aims to enhance sustainability of conducting clinical trials on the African continent. A number of projects focuses on creating and developing capacity for ethics review of clinical trials and of enhancing the regulatory framework needed for approval of medicines in Africa. This enables African countries to conduct high-quality and ethically sound clinical trials, and to assess the safety and efficacy of all medicines that enter the African market.

EU Member State commitment and African leadership very encouraging
European Science and Research Commissioner Janez Potocnik underlined the integration of policies achieved by the partnership: "This decision from the EDCTP General Assembly shows the commitment of the participating countries and the European Commission in the fight against the three main poverty-related diseases in and for Africa. We're confident that our cooperation with African researchers will make a difference".

Prof. Charles Mgone, EDCTP’s executive director expressed the significance of the approval when he said: “This is a very significant milestone for collaboration between north and south in the fight against the three main diseases of poverty namely HIV/AIDS, tuberculosis and malaria. It is also very gratifying to note that among the 26 projects approved for funding 22 have African scientists based in Africa as their principal investigators. This underscores EDCTP’s objective of fostering a genuine partnership and enhancing clinical research capacity in Africa.”

About EDCTP
EDCTP aims through research integration to accelerate the development of new or improved drugs, vaccines, diagnostics and microbicides against HIV/AIDS, malaria and tuberculosis, with a focus on phase II and III clinical trials in sub-Saharan Africa.

EDCTP supports integrated multicentre projects which combine clinical trials, capacity building and networking. The aim of integrating these three activities is to develop the capacity to conduct clinical trials in sub-Saharan Africa in a sustainable way.

The basis of EDCTP is partnership. It unites 14 participating European Union (EU) Member States plus Norway and Switzerland with sub-Saharan African countries. The partnership helps EU Member States to integrate and coordinate their own national research and development programmes and form partnerships with their African counterparts.

Ilona van den Brink | alfa
Further information:
http://ec.europa.eu/research/index.cfm
http://www.edctp.org/index.php?id=428

More articles from Health and Medicine:

nachricht Routing gene therapy directly into the brain
07.12.2017 | Boston Children's Hospital

nachricht New Hope for Cancer Therapies: Targeted Monitoring may help Improve Tumor Treatment
01.12.2017 | Berliner Institut für Gesundheitsforschung / Berlin Institute of Health (BIH)

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Scientists channel graphene to understand filtration and ion transport into cells

Tiny pores at a cell's entryway act as miniature bouncers, letting in some electrically charged atoms--ions--but blocking others. Operating as exquisitely sensitive filters, these "ion channels" play a critical role in biological functions such as muscle contraction and the firing of brain cells.

To rapidly transport the right ions through the cell membrane, the tiny channels rely on a complex interplay between the ions and surrounding molecules,...

Im Focus: Towards data storage at the single molecule level

The miniaturization of the current technology of storage media is hindered by fundamental limits of quantum mechanics. A new approach consists in using so-called spin-crossover molecules as the smallest possible storage unit. Similar to normal hard drives, these special molecules can save information via their magnetic state. A research team from Kiel University has now managed to successfully place a new class of spin-crossover molecules onto a surface and to improve the molecule’s storage capacity. The storage density of conventional hard drives could therefore theoretically be increased by more than one hundred fold. The study has been published in the scientific journal Nano Letters.

Over the past few years, the building blocks of storage media have gotten ever smaller. But further miniaturization of the current technology is hindered by...

Im Focus: Successful Mechanical Testing of Nanowires

With innovative experiments, researchers at the Helmholtz-Zentrums Geesthacht and the Technical University Hamburg unravel why tiny metallic structures are extremely strong

Light-weight and simultaneously strong – porous metallic nanomaterials promise interesting applications as, for instance, for future aeroplanes with enhanced...

Im Focus: Virtual Reality for Bacteria

An interdisciplinary group of researchers interfaced individual bacteria with a computer to build a hybrid bio-digital circuit - Study published in Nature Communications

Scientists at the Institute of Science and Technology Austria (IST Austria) have managed to control the behavior of individual bacteria by connecting them to a...

Im Focus: A space-time sensor for light-matter interactions

Physicists in the Laboratory for Attosecond Physics (run jointly by LMU Munich and the Max Planck Institute for Quantum Optics) have developed an attosecond electron microscope that allows them to visualize the dispersion of light in time and space, and observe the motions of electrons in atoms.

The most basic of all physical interactions in nature is that between light and matter. This interaction takes place in attosecond times (i.e. billionths of a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

AKL’18: The opportunities and challenges of digitalization in the laser industry

07.12.2017 | Event News

Blockchain is becoming more important in the energy market

05.12.2017 | Event News

 
Latest News

New research identifies how 3-D printed metals can be both strong and ductile

11.12.2017 | Physics and Astronomy

Scientists channel graphene to understand filtration and ion transport into cells

11.12.2017 | Materials Sciences

What makes corals sick?

11.12.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>